JP2008518608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518608A5 JP2008518608A5 JP2007539463A JP2007539463A JP2008518608A5 JP 2008518608 A5 JP2008518608 A5 JP 2008518608A5 JP 2007539463 A JP2007539463 A JP 2007539463A JP 2007539463 A JP2007539463 A JP 2007539463A JP 2008518608 A5 JP2008518608 A5 JP 2008518608A5
- Authority
- JP
- Japan
- Prior art keywords
- lna oligonucleotide
- lna
- composition
- conjugate
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 4
- 230000002491 angiogenic effect Effects 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000000260 Warts Diseases 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000010153 skin papilloma Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62656304P | 2004-11-09 | 2004-11-09 | |
| US60/626,563 | 2004-11-09 | ||
| US64718605P | 2005-01-25 | 2005-01-25 | |
| US60/647,186 | 2005-01-25 | ||
| US69972105P | 2005-07-15 | 2005-07-15 | |
| US60/699,721 | 2005-07-15 | ||
| US72462105P | 2005-10-07 | 2005-10-07 | |
| US60/724,621 | 2005-10-07 | ||
| PCT/DK2005/000721 WO2006050734A2 (en) | 2004-11-09 | 2005-11-09 | Potent lna oligonucleotides for the inhibition of hif-1a expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011177731A Division JP2011229540A (ja) | 2004-11-09 | 2011-08-15 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008518608A JP2008518608A (ja) | 2008-06-05 |
| JP2008518608A5 true JP2008518608A5 (OSRAM) | 2008-11-27 |
| JP4825807B2 JP4825807B2 (ja) | 2011-11-30 |
Family
ID=36177326
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539463A Expired - Fee Related JP4825807B2 (ja) | 2004-11-09 | 2005-11-09 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
| JP2011177731A Withdrawn JP2011229540A (ja) | 2004-11-09 | 2011-08-15 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
| JP2014031436A Withdrawn JP2014098027A (ja) | 2004-11-09 | 2014-02-21 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011177731A Withdrawn JP2011229540A (ja) | 2004-11-09 | 2011-08-15 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
| JP2014031436A Withdrawn JP2014098027A (ja) | 2004-11-09 | 2014-02-21 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7589190B2 (OSRAM) |
| EP (1) | EP1833840B9 (OSRAM) |
| JP (3) | JP4825807B2 (OSRAM) |
| KR (1) | KR101176245B1 (OSRAM) |
| AT (1) | ATE476441T1 (OSRAM) |
| AU (1) | AU2005304112B2 (OSRAM) |
| BR (1) | BRPI0515726A8 (OSRAM) |
| CA (1) | CA2587173C (OSRAM) |
| DE (1) | DE602005022768D1 (OSRAM) |
| DK (1) | DK1833840T3 (OSRAM) |
| EA (1) | EA014097B1 (OSRAM) |
| IL (1) | IL183054A0 (OSRAM) |
| MX (1) | MX2007005558A (OSRAM) |
| NO (1) | NO341878B1 (OSRAM) |
| NZ (1) | NZ555644A (OSRAM) |
| WO (1) | WO2006050734A2 (OSRAM) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1569661B1 (en) | 2002-11-18 | 2009-09-09 | Santaris Pharma A/S | Antisense design |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| JP4755972B2 (ja) | 2003-03-21 | 2011-08-24 | サンタリス ファーマ アー／エス | 短鎖干渉ＲＮＡ（ｓｉＲＮＡ）アナログ |
| WO2005073378A1 (en) * | 2004-01-30 | 2005-08-11 | Santaris Pharma A/S | MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA) |
| US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
| US7589190B2 (en) * | 2004-11-09 | 2009-09-15 | Enzon Pharmaceuticals, Inc. | Potent LNA oligonucleotides for the inhibition of HIF-1A expression |
| US8288354B2 (en) | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
| CA2638837A1 (en) * | 2006-01-27 | 2007-08-02 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
| US8329888B2 (en) | 2006-03-23 | 2012-12-11 | Santaris Pharma A/S | Small internally segmented interfering RNA |
| JP5825754B2 (ja) | 2006-05-05 | 2015-12-02 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ａｐｏｂの発現を調節するための化合物および方法 |
| EP2076257A4 (en) * | 2006-09-15 | 2014-04-16 | Belrose Pharma Inc | POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS |
| EP2149605B1 (en) | 2007-03-22 | 2013-07-03 | Santaris Pharma A/S | Short RNA antagonist compounds for the modulation of target mRNA |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| WO2009020119A1 (ja) * | 2007-08-06 | 2009-02-12 | Senju Pharmaceutical Co., Ltd. | ＨＩＦ－１αおよびＨＩＦ－２α発現阻害物質含有医薬 |
| DK2195428T3 (en) | 2007-09-19 | 2014-03-03 | Applied Biosystems Llc | SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF |
| JP2010539961A (ja) * | 2007-10-04 | 2010-12-24 | サンタリス ファーマ アー／エス | ＨＩＦ１αの調節のための短いＲＮＡアンタゴニスト化合物 |
| MX339820B (es) | 2008-10-03 | 2016-06-13 | Curna Inc | Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1. |
| KR101866152B1 (ko) | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
| ES2600781T3 (es) | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
| CN102317458B (zh) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 |
| EP3009150B1 (en) | 2009-02-12 | 2019-11-13 | CuRNA, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| WO2010107733A2 (en) | 2009-03-16 | 2010-09-23 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
| WO2010107740A2 (en) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| EP2427552B1 (en) | 2009-05-06 | 2016-11-16 | CuRNA, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
| CN103223177B (zh) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| EP2427554B1 (en) | 2009-05-08 | 2016-11-16 | CuRNA, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
| EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
| US8895527B2 (en) | 2009-05-22 | 2014-11-25 | Curna, Inc. | Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 |
| JP5960049B2 (ja) | 2009-05-28 | 2016-08-02 | クルナ・インコーポレーテッド | 抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療 |
| US8951981B2 (en) | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
| CN102695797B (zh) | 2009-06-16 | 2018-05-25 | 库尔纳公司 | 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病 |
| CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| KR101801407B1 (ko) | 2009-07-24 | 2017-11-24 | 큐알엔에이, 인크. | 시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료 |
| JP6128848B2 (ja) | 2009-08-05 | 2017-05-17 | クルナ・インコーポレーテッド | インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療 |
| CA2770104C (en) | 2009-08-11 | 2019-03-19 | Opko Curna, Llc | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| WO2011022606A2 (en) | 2009-08-21 | 2011-02-24 | Curna, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
| CN102482671B (zh) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病 |
| US20120295952A1 (en) | 2009-09-25 | 2012-11-22 | Curna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
| AR078770A1 (es) | 2009-10-27 | 2011-11-30 | Elara Pharmaceuticals Gmbh | Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas. |
| RU2639550C2 (ru) | 2009-12-16 | 2017-12-21 | Курна, Инк. | Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1 |
| CN102781480B (zh) | 2009-12-23 | 2018-07-27 | 库尔纳公司 | 通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病 |
| US8940708B2 (en) | 2009-12-23 | 2015-01-27 | Curna, Inc. | Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF |
| EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| JP5982288B2 (ja) | 2009-12-29 | 2016-08-31 | カッパーアールエヌエー，インコーポレイテッド | 腫瘍タンパク質６３（ｐ６３）に対する天然アンチセンス転写物の阻害による腫瘍タンパク質６３関連疾患の治療 |
| EP2519632B1 (en) | 2009-12-31 | 2018-04-11 | CuRNA, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
| RU2611187C2 (ru) | 2010-01-04 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8 |
| EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
| KR101854926B1 (ko) | 2010-01-11 | 2018-05-04 | 큐알엔에이, 인크. | 성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료 |
| CA2786568A1 (en) | 2010-01-25 | 2011-07-28 | Curna, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
| JP5976548B2 (ja) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー，インコーポレイテッド | Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療 |
| CA2795145C (en) | 2010-04-02 | 2019-01-22 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
| CN102858979B (zh) | 2010-04-09 | 2018-01-26 | 库尔纳公司 | 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病 |
| KR20130101442A (ko) | 2010-05-03 | 2013-09-13 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
| TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| DK2576783T3 (en) | 2010-05-26 | 2018-03-12 | Curna Inc | TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1 |
| EP2576784B1 (en) | 2010-05-26 | 2017-11-15 | CuRNA, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
| CA2801342A1 (en) * | 2010-06-04 | 2011-12-08 | Eric N. Olson | Regulation of metabolism by mir-378 |
| JP6023705B2 (ja) | 2010-06-23 | 2016-11-09 | カッパーアールエヌエー，インコーポレイテッド | ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療 |
| EP2593547B1 (en) | 2010-07-14 | 2017-11-15 | CuRNA, Inc. | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
| KR101886457B1 (ko) | 2010-10-06 | 2018-08-07 | 큐알엔에이, 인크. | 시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료 |
| CN103180445B (zh) | 2010-10-22 | 2018-02-16 | 库尔纳公司 | 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病 |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| CA2818824A1 (en) | 2010-11-23 | 2012-05-31 | Joseph Collard | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| RU2620980C2 (ru) | 2011-06-09 | 2017-05-30 | Курна, Инк. | Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn |
| JP6125505B2 (ja) | 2011-09-06 | 2017-05-10 | カッパーアールエヌエー，インコーポレイテッド | 小分子による電位開口型ナトリウムチャネル・アルファサブユニット関連疾患の治療 |
| TR201815503T4 (tr) | 2012-03-15 | 2018-11-21 | Curna Inc | Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi. |
| US20150291958A1 (en) * | 2012-11-15 | 2015-10-15 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| EP3003392B1 (en) * | 2013-06-04 | 2019-10-23 | President and Fellows of Harvard College | Rna-guideded transcriptional regulation |
| CN109312403B (zh) | 2016-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | 体外肾毒性筛选测定法 |
| WO2017216340A1 (en) * | 2016-06-17 | 2017-12-21 | F. Hoffmann-La Roche Ag | In vitro nephrotoxicity screening assay |
| WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5278324A (en) | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
| MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US5227400A (en) | 1991-09-23 | 1993-07-13 | Florida State University | Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them |
| US5250683A (en) | 1991-09-23 | 1993-10-05 | Florida State University | Certain substituted taxanes and pharmaceutical compositions containing them |
| US5272171A (en) | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
| FR2688518B1 (fr) | 1992-03-13 | 1994-05-06 | Rhone Poulenc Rorer Sa | Procede de preparation de derives du taxane. |
| US5248796A (en) | 1992-06-18 | 1993-09-28 | Bristol-Myers Squibb Company | Taxol derivatives |
| US5254580A (en) | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5882914A (en) | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| AU3455599A (en) | 1998-03-27 | 1999-10-18 | Board Of Trustees Of The Leland Stanford Junior University | Hypoxia-inducible human genes, proteins, and uses thereof |
| US6821724B1 (en) | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
| CN1350542A (zh) | 1999-03-18 | 2002-05-22 | 埃克西库恩公司 | 木－lna类似物 |
| ES2269113T3 (es) | 1999-03-24 | 2007-04-01 | Exiqon A/S | Sintesis mejorada de -2.2.1 / biciclo-nucleosidos. |
| US6350868B1 (en) | 1999-04-26 | 2002-02-26 | University Of North Carolina At Chapel Hill | Antisense human fucosyltransferase sequences and methods of use thereof |
| JP2002543214A (ja) | 1999-05-04 | 2002-12-17 | エクシコン エ／エス | Ｌ−リボ−ｌｎａ類縁体 |
| AU5717400A (en) | 1999-06-14 | 2001-01-02 | Cancer Research Ventures Limited | Cancer therapy |
| JP2003502383A (ja) | 1999-06-21 | 2003-01-21 | マードック チルドレンズ リサーチ インスティチュート | 医学的障害の予防及び／又は治療のための方法 |
| US6168950B1 (en) | 1999-07-23 | 2001-01-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEKK1 expression |
| IL148916A0 (en) | 1999-10-04 | 2002-09-12 | Exiqon As | Design of high affinity rnase h recruiting oligonucleotide |
| US6706505B1 (en) | 2000-03-08 | 2004-03-16 | Amgen Inc | Human E3α ubiquitin ligase family |
| AU2001295531A1 (en) | 2000-09-02 | 2002-03-13 | Grünenthal GmbH | Antisense oligonucleotides against vanilloid receptor 1 |
| DE60119562T2 (de) | 2000-10-04 | 2007-05-10 | Santaris Pharma A/S | Verbesserte synthese von purin-blockierten nukleinsäure-analoga |
| US7105656B2 (en) | 2000-10-26 | 2006-09-12 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating hematologic malignancies and multiple drug resistance |
| WO2002094250A2 (en) | 2001-05-18 | 2002-11-28 | Cureon A/S | Therapeutic uses of lna-modified oligonucleotides in infectious diseases |
| WO2002099104A1 (fr) | 2001-06-05 | 2002-12-12 | Pola Chemical Industries Inc. | Polypeptide destabilisant une proteine dans des cellules dans des conditions aerobies et adn codant pour ce polypeptide |
| EP1409497B1 (en) | 2001-07-12 | 2005-01-19 | Santaris Pharma A/S | Method for preparation of lna phosphoramidites |
| US7153954B2 (en) | 2001-07-12 | 2006-12-26 | Santaris Pharma A/S | Method for preparation of LNA phosphoramidites |
| JP4338527B2 (ja) * | 2002-04-05 | 2009-10-07 | サンタリス ファーマ アー／エス | ＨＩＦ−１α発現を調節するオリゴマー化合物 |
| WO2003095467A1 (en) | 2002-05-08 | 2003-11-20 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| CA2504926C (en) * | 2002-11-01 | 2014-01-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of hif-1 alpha |
| EP1569661B1 (en) | 2002-11-18 | 2009-09-09 | Santaris Pharma A/S | Antisense design |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| CA2515623A1 (en) | 2003-02-10 | 2004-08-19 | Santaris Pharma A/S | Oligomeric compounds for the modulation of survivin expression |
| US20040248840A1 (en) | 2003-02-10 | 2004-12-09 | Santaris Pharma A/S | Oligomeric compounds for the modulation of ras expression |
| US7589190B2 (en) * | 2004-11-09 | 2009-09-15 | Enzon Pharmaceuticals, Inc. | Potent LNA oligonucleotides for the inhibition of HIF-1A expression |
-
2005
- 2005-11-09 US US11/271,686 patent/US7589190B2/en not_active Expired - Fee Related
- 2005-11-09 CA CA2587173A patent/CA2587173C/en not_active Expired - Fee Related
- 2005-11-09 DK DK05800760.0T patent/DK1833840T3/da active
- 2005-11-09 MX MX2007005558A patent/MX2007005558A/es unknown
- 2005-11-09 AT AT05800760T patent/ATE476441T1/de not_active IP Right Cessation
- 2005-11-09 KR KR1020077012303A patent/KR101176245B1/ko not_active Expired - Fee Related
- 2005-11-09 NZ NZ555644A patent/NZ555644A/en not_active IP Right Cessation
- 2005-11-09 BR BRPI0515726A patent/BRPI0515726A8/pt not_active Application Discontinuation
- 2005-11-09 AU AU2005304112A patent/AU2005304112B2/en not_active Ceased
- 2005-11-09 DE DE602005022768T patent/DE602005022768D1/de not_active Expired - Lifetime
- 2005-11-09 EP EP05800760A patent/EP1833840B9/en not_active Expired - Lifetime
- 2005-11-09 EA EA200701033A patent/EA014097B1/ru not_active IP Right Cessation
- 2005-11-09 WO PCT/DK2005/000721 patent/WO2006050734A2/en not_active Ceased
- 2005-11-09 JP JP2007539463A patent/JP4825807B2/ja not_active Expired - Fee Related
-
2007
- 2007-05-08 IL IL183054A patent/IL183054A0/en not_active IP Right Cessation
- 2007-06-08 NO NO20072933A patent/NO341878B1/no not_active IP Right Cessation
-
2009
- 2009-06-03 US US12/477,261 patent/US7939507B2/en active Active
-
2011
- 2011-04-04 US US13/079,525 patent/US8410071B2/en not_active Expired - Fee Related
- 2011-08-15 JP JP2011177731A patent/JP2011229540A/ja not_active Withdrawn
-
2014
- 2014-02-21 JP JP2014031436A patent/JP2014098027A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518608A5 (OSRAM) | ||
| JP6899509B2 (ja) | 呼吸器疾患関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含む呼吸器疾患予防または治療用組成物 | |
| JP2022036182A (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| KR102208588B1 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| JP5981625B2 (ja) | Ｈｓｆ１関連疾患を処置するための有機組成物 | |
| JP2022515503A (ja) | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 | |
| JP2016513976A5 (OSRAM) | ||
| JP2022534702A (ja) | 核酸、薬物組成物及び複合体ならびに調製方法と使用 | |
| WO2013105022A2 (en) | Organic compositions to treat beta-catenin-related diseases | |
| JP2021524277A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| WO2018048888A1 (en) | Pd-1 specific aptamers | |
| JP6368363B2 (ja) | デングウィルス特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含むデングウィルス増殖抑制用組成物 | |
| US9233119B2 (en) | Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells | |
| WO2016145362A2 (en) | Inhibitors of dek protein and related methods | |
| JP7464709B2 (ja) | Ｃｔｇｆ遺伝子特異的二重鎖オリゴヌクレオチド及びこれを含む線維症関連疾患及び呼吸器関連疾患の予防及び治療用組成物 | |
| JP5730508B2 (ja) | 炎症性腸疾患の治療又は予防剤 | |
| JP5777240B2 (ja) | 新規オリゴヌクレオチド誘導体及びそれから成るＮＦ−κＢデコイ | |
| WO2016109522A1 (en) | Particle-nucleic acid conjugates and therapeutic uses related thereto | |
| HK40016323A (en) | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease | |
| BR112016000163B1 (pt) | Estrutura de oligo rna de dupla hélice, nanopartículas, composição farmacêutica e formulação liofilizada | |
| AU2017201838A1 (en) | Organic compositions to treat Beta-ENac-related diseases | |
| NZ788062A (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection | |
| AU2017200586A1 (en) | Organic compositions to treat HSF1-related diseases |